Naltrexone-bupropion (Mysimba) : Licensed in the UK for weight management, though not widely commissioned within the NHS and without a NICE technology appraisal recommending routine use
Institutional Review Board Statement Not applicable
The main effect of treatment also significant (F( 1,54 ) = 2.791, R 2 = 0.040, p = 0.080), and there was a trend towards a significant main effect of diet (main effect of diet: F( 1,54 ) = 6.413, R 2 = 0.093, p = 0.008)
This leads to the inhibition of inflammatory reactions and acceleration of neuron regeneration through the secretion of interleukin-10, thereby playing an important role in suppressing immunity and neuroprotection in the context of ischemic stroke
Patients should always inform their surgical team and anaesthetist about GLP-1 use, including the specific medication, dose, and timing of the last administration, to ensure appropriate perioperative planning
10.1038/s41598-019-51880-9 [DOI] [PMC free article] [PubMed] [Google Scholar] Thiebaud, N